PsiOxus Therapeutics Ltd. (PsiOxus) is a UK and US based cancer therapeutics company recently listed 25th in the Sunday Times Hiscox Tech Track 100 in 2017 for its ‘Gene Therapy for Cancer’ platform technology. PsiOxus has recently expanded into 21,000 sq ft of new facilities including a state of the art research and development laboratory in The Quadrant at the Abingdon Science Park.
The main contractor, Morgan Lovell specified Selectaglaze, the leading supplier of secondary glazing to come up with bespoke solutions to improve the thermal insulation and security of the building in specific areas.
The original primary windows were thermally inefficient, draughty and let heat escape. PsiOxus’ research and development environment demands the utmost cleanliness so a glazing solution was required to meet these requirements. As part of the refurbishment, windows with fire ratings separating the labs and corridors were also required to conform to building regulations.
Selectaglaze met the brief by installing a total of 15 horizontal slider units with 6mm toughened low- E glass in the 2 and 3 pane options to all of the external primary windows. The inverted u-channel section was included to sit in the bottom of each frame to minimise the dust traps and enhance the ease of cleaning. All of the secondary glazing on the ground floor was fitted with Satinovo obscurity glass to provide increased lab privacy.
In addition, a total of 22 Series 40 fixed light units were fitted as viewing panels in the research and development laboratories. The vision panels within the internal walls were fitted in 6mm toughened glass, and in the lab areas, units were fitted with a 10mm Pyrodur glass, providing 30 minutes of fire integrity.
Selectaglaze is the leading specialist in secondary glazing, established in 1966 and Royal Warrant Holder since 2004.